Jason Smith
Net Worth

Last updated:

What is Jason Smith net worth?

The estimated net worth of Mr. Jason Smith is at least $2,701,846 as of 27 Sep 2025. He owns shares worth $356,715 as insider, has earned $317,261 from insider trading and has received compensation worth at least $2,027,870 in Real Matters Inc. and UroGen Pharma Ltd..

What is the salary of Jason Smith?

Mr. Jason Smith salary is $673,750 per year as Founder & Executive Chairman in Real Matters Inc.. He also receives $338,530 as Gen. Counsel & Chief Compliance Officer in UroGen Pharma Ltd..

How old is Jason Smith?

Mr. Jason Smith is 50 years old, born in 1975.

What stocks does Jason Smith currently own?

As insider, Mr. Jason Smith owns shares in one company:

Company Title Shares Price per share Total value
UroGen Pharma Ltd. (URGN) Gen. Counsel & Chief Compliance Officer 18,824 $18.95 $356,715

What does UroGen Pharma Ltd. do?

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN logo
URGN
UroGen Pharma Ltd.
$18.95

Jason Smith insider trading

UroGen Pharma Ltd.

Mr. Jason Smith has made 12 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,248 units of URGN stock worth $19,693 on 1 Feb 2024.

The largest trade he's ever made was exercising 8,334 units of URGN stock on 31 Aug 2023. As of 27 Sep 2025 he still owns at least 18,824 units of URGN stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Ordinary Shares 1,248 $15.78 $19,693
Sale
Ordinary Shares 417 $15.78 $6,580
Sale
Ordinary Shares 3,328 $15.78 $52,516
Option
Ordinary Shares 834 N/A N/A
Option
Restricted Stock Units 834 N/A N/A
Option
Restricted Stock Units 2,500 N/A N/A
Option
Restricted Stock Units 6,666 N/A N/A
Option
Ordinary Shares 2,500 N/A N/A
Option
Ordinary Shares 6,666 N/A N/A
Sale
Ordinary Shares 417 $15.74 $6,564
Sale
Ordinary Shares 1,248 $15.74 $19,644
Sale
Ordinary Shares 3,328 $15.74 $52,383
Option
Ordinary Shares 8,334 N/A N/A
Option
Restricted Stock Units 8,334 N/A N/A
Sale
Ordinary Shares 3,800 $18.01 $68,438
Option
Restricted Stock Units 833 N/A N/A
Option
Ordinary Shares 2,500 N/A N/A
Option
Restricted Stock Units 833 N/A N/A
Sale
Ordinary Shares 409 $10.12 $4,139
Sale
Ordinary Shares 1,227 $10.12 $12,417
Option
Restricted Stock Units 2,500 N/A N/A
Option
Restricted Stock Units 2,500 N/A N/A
Option
Ordinary Shares 833 N/A N/A
Option
Ordinary Shares 8,333 N/A N/A
Sale
Ordinary Shares 3,606 $7.21 $25,999
Option
Restricted Stock Units 8,333 N/A N/A
Sale
Ordinary Shares 414 $7.58 $3,138
Option
Ordinary Shares 833 N/A N/A
Option
Restricted Stock Units 833 N/A N/A
Option
Restricted Stock Units 8,333 N/A N/A
Sale
Ordinary Shares 3,803 $12.03 $45,750
Option
Ordinary Shares 8,333 N/A N/A
Purchase
Common Stock 2,500 $15.71 $39,275

Real Matters key executives

Real Matters Inc. executives and other stock owners filed with the SEC:

  • Mr. Brian Lang (56) Chief Executive Officer & Director
  • Mr. Jason Smith (50) Founder & Executive Chairman
  • Mr. Robert John Smith (64) Executive Vice President of Corporation Devel.